Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,855
  • Shares Outstanding, K 18,052
  • Annual Sales, $ 60 K
  • Annual Income, $ -22,270 K
  • 60-Month Beta 0.42
  • Price/Sales 798.55
  • Price/Cash Flow N/A
  • Price/Book 3.67
Trade GANX with:

Options Overview Details

View History
  • Implied Volatility 84.79% ( -11.59%)
  • Historical Volatility 119.90%
  • IV Percentile 32%
  • IV Rank 12.24%
  • IV High 578.51% on 07/17/24
  • IV Low 15.90% on 11/09/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 295
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,291
  • Open Int (30-Day) 1,218

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +37.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +113.48%
on 09/09/24
2.1400 -0.23%
on 10/07/24
+1.0900 (+103.33%)
since 09/06/24
3-Month
0.8900 +139.89%
on 08/13/24
2.1400 -0.23%
on 10/07/24
+0.9300 (+77.92%)
since 07/05/24
52-Week
0.8900 +139.89%
on 08/13/24
5.3300 -59.94%
on 02/07/24
-1.2500 (-36.83%)
since 10/06/23

Most Recent Stories

More News
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GANX : 2.1300 (+17.31%)
Gain Therapeutics to Participate at Upcoming Investor Conferences

GANX : 2.1300 (+17.31%)
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and...

GANX : 2.1300 (+17.31%)
Gain Therapeutics to Participate at the Jefferies Healthcare Conference

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming...

GANX : 2.1300 (+17.31%)
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming...

GANX : 2.1300 (+17.31%)
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in...

GANX : 2.1300 (+17.31%)
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in...

GANX : 2.1300 (+17.31%)
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress

Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal Models...

GANX : 2.1300 (+17.31%)
Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming...

GANX : 2.1300 (+17.31%)
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting

Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and...

GANX : 2.1300 (+17.31%)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 2.5600
2nd Resistance Point 2.3500
1st Resistance Point 2.2400
Last Price 2.1300
1st Support Level 1.9300
2nd Support Level 1.7200
3rd Support Level 1.6100

See More

52-Week High 5.3300
Fibonacci 61.8% 3.6300
Fibonacci 50% 3.1100
Fibonacci 38.2% 2.5900
Last Price 2.1300
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar